ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Vaccine · 2026-07-21

In 903 adults in Pakistan primed with Sinovac, AZD1222 or natural infection, ½ and ⅓ dose BNT162b2 boosters were non-inferior to full-dose Sinovac (day-28 seroresponse 66.7% and 70.5% vs 19.4%) but not to full-dose BNT162b2 in any priming group. No serious adverse events.

RCTn = 903
Hussain et al. Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan
Infectious diseases · Vaccine · 2026-06-27

In 31 previously infected children aged 5–11 (trial stopped early), one dose of BNT162b2 gave similar day-28 neutralising antibody titres to two doses (GMR 0.9; 95% CI 0.5–1.6), but non-inferiority could not be shown as the trial was underpowered.

RCTn = 31
Prat-Aymerich et al. A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial)
Infectious diseases · Lancet HIV · 2026-02-11

Phase 2a RCT in South Africa (694 adults; 588 with HIV in primary analysis): a single boost of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN raised antibodies by day 15 (neutralising GMFC 2.6, 10.0 and 4.5). Reactions were mostly mild; no safety issues.

RCTn = 694
Govender et al. Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial
Infectious diseases · Int J Infect Dis · 2026-02-06

Final report of an RCT in 322 adults aged ≥75: double-dose mRNA-1273 boosters gave numerically higher 12-month antibody levels and neutralisation than BNT162b2; second-booster twofold antibody rise was 87.2% vs 78.5% (P=0.056); grade 2 reactions were more frequent.

RCTn = 322
Stemler et al. Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report
Infectious diseases · J Infect · 2025-12-01

Phase II RCT in 281 UK adolescents aged 12-15 given a third COVID-19 dose: 10 μg adult-formulation BNT162b2 was non-inferior and superior to 10 μg paediatric BNT162b2 for anti-spike IgG at day 28 (aGMR 1.50); reactions were mostly mild to moderate.

Clinical trialn = 281
Kelly et al. Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.